Profile
Artenga’s microbubble drug conjugates (MDC) and focused ultrasound (FUS) are key enablers for:
- Safe, non-invasive, targeted blood brain barrier drug delivery
- Boosting immunotherapy efficacy without added toxicity
- Our Sunnybrook collaborators did first clinical FUS and non-drug microbubble BBB opening for glioblastoma, Alzheimer’s, breast cancer, brain mets, ALS and Parkinson’s.
Differentiation factors are:
- Higher dose delivered with greater perfusion
- Liver clearance to mitigate systemic effects
- AAV MDC and new tech planned to limit transduction to diseased brain regions

Website
Contact
-
James Keenan, Chief Executive OfficerTel: +1 613 322-8585Email: jkeenan@artenga.com
-
-
-
-
-
Event details
Date: September 13 - 15, 2021
Event contact
Patricia Cosgrove
Area Director
USA: Life Sciences
Tel: +1 647-293-6306
Email: patricia.cosgrove@ontario.ca
Participants
6 in total
-
Artenga’s microbubble drug conjugates (MDC) and focused ultrasound (FUS) are key…
-
KA Imaging has created color x-ray, which allows for early and more accurate diagnostics with higher radiology…
-
Mediphage Bioceuticals, a preclinical-stage biotechnology company, is developing a next-generation non-viral gene…
-
Nanology Labs, a University of Toronto spin-off company, has developed a novel drug delivery platform technology…
-
Nucro-Technics is a full-service Contract Support Organization that specializes in the conduct of both GLP…
-
PocketMD is a 24/7 healthcare marketplace that connects patients with doctors and allied health professionals…